- Conditions
- Type 1 Diabetes, Diabetes Mellitus, Type 1
- Interventions
- CELZ-201 Administration, Control Group
- Biological · Other
- Lead sponsor
- Creative Medical Technology Holdings Inc
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 14,110
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Placebo, DT120
- Other · Drug
- Lead sponsor
- Definium Therapeutics US, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 34
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Bicifadine
- Drug
- Lead sponsor
- XTL Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Paducah, Kentucky
- Conditions
- Healthy
- Interventions
- Placebo, JNJ-64281802 High dose, JNJ-64281802 Medium dose, JNJ-64281802 Low dose, JNJ-64281802 Dosing Regimen X, JNJ-64281802 Dosing Regimen Y, JNJ-64281802 Dosing Regimen Z
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 109
- States / cities
- Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
- Conditions
- Hypertension, Stage 2 Hypertension, Diabetes
- Interventions
- Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 95
- States / cities
- Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more
- Conditions
- Hypertension, Heart Failure
- Interventions
- Clevidipine, Standard of Care IV antihypertensive
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 9
- States / cities
- Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more
- Conditions
- Hepatic Impairment
- Interventions
- Midostaurin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy
- Interventions
- PF-06252616, Placebo, PF-06252161
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Lupus Nephritis (LN)
- Interventions
- Atacicept, Placebo
- Drug
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • La Jolla, California • La Palma, California + 19 more
- Conditions
- Huntington's Disease
- Interventions
- PF-02545920, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- Peripheral Neuropathy, Neuropathic Pain
- Interventions
- ADL5859, Duloxetine, Placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 27
- States / cities
- Riverside, California • Torrance, California • Kissimmee, Florida + 21 more
- Conditions
- Post Traumatic Stress Disorder, Depression, Violence
- Interventions
- BSHAPE, Control (general wellness)
- Behavioral · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 676 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Coronary Syndrome
- Interventions
- Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,037 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 49
- States / cities
- Alexander City, Alabama • Banning, California • Sylmar, California + 46 more
- Conditions
- Intraosseous Vascular Access
- Interventions
- EZ-IO
- Device
- Lead sponsor
- Vidacare Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Benign Prostatic Hypertrophy
- Interventions
- Ozarelix, Placebo
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 10 more
- Conditions
- Alzheimer's Disease
- Interventions
- ELND005, Placebo
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Encino, California + 50 more
- Conditions
- Gingivitis, Plaque
- Interventions
- Colgate® Cavity Protection Toothpaste, Listerine® Cool Mint®, Concept Curve Winter Series Toothbrush, 5% Hydroalcohol Mouthrinse, Mouthrinse Prototype 1, Mouthrinse Prototype 2
- Other
- Lead sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Fort Wayne, Indiana
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Fazirsiran Injection, Placebo
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
- Conditions
- Chemotherapy Exposure, Handling Guidelines, Oncology Nurse, Adherence
- Interventions
- The Workplace program to Improve the Safe Handling of hazardous drugs (WISH)
- Behavioral
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Acute Kidney Injury
- Interventions
- GDC-8264, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 9
- States / cities
- Stanford, California • Tampa, Florida • Lutherville, Maryland + 6 more
- Conditions
- Angioedema
- Interventions
- Lanadelumab
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 12 more
- Conditions
- Heart Failure
- Interventions
- Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • Lake Forest, California • Santa Maria, California + 18 more
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Interventions
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 67
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more